Biotech Backers Learn To Live With Exit-By-Earn-Out
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?